Hemodiafiltration - A New Era

Hemodiafiltration - A New Era

von: H. Kawanishi, A.C. Yamashita

Karger, 2010

ISBN: 9783805595612 , 228 Seiten

Format: PDF, ePUB, OL

Kopierschutz: DRM

Windows PC,Mac OSX geeignet für alle DRM-fähigen eReader Apple iPad, Android Tablet PC's Apple iPod touch, iPhone und Android Smartphones Online-Lesen für: Windows PC,Mac OSX,Linux

Preis: 236,81 EUR

Mehr zum Inhalt

Hemodiafiltration - A New Era


 

Cover

1

Contents

6

Preface

9

History and Evolution of Hemodiafiltration

11

Dawn of Hemodiafiltration

11

Abstract

11

First 60 Years (1914 – Early 1970s)

11

Middle Molecule Hypothesis and HF

12

Development of HDF

12

The Current Status of HDF in Japan

13

References

14

Hemodiafiltration – State of the Art

15

Abstract

15

Online Hemodiafiltration

19

References

25

Hemodiafiltration: Evolution of a Technique towards Better Dialysis Care

29

Abstract

29

Hemodiafiltration: From Origin to Today

29

Techniques of Hemodiafiltration

30

Mechanism of Hemodiafiltration

33

Clinical Outcomes Achieved by HDF

34

Conclusion

36

References

36

Clinical Benefits of Hemodiafiltration

38

Optimal Therapeutic Conditions for Online Hemodiafiltration

38

Abstract

38

Technical Prerequisite and Basic Hygienic Rules for ol-HDF

39

Prerequisite and Technical Options of ol-HDF

41

ol-HDF Prescription in Practice

44

Handling and Microbial Monitoring of ol-HDF

44

Conclusions

45

References

45

Effect of Hemodiafiltration on Mortality, Inflammation and Quality of Life

49

Abstract

49

Mortality

50

Inflammation

51

Health-Related Quality of Life

55

Treatment Optimization Parameters

57

Conclusion

58

References

58

How to Prescribe Hemodialysis or Hemodiafiltration in Order to Ameliorate Dialysis-Related Symptoms and Complications

63

Abstract

63

Classical Parameters for Prescribing a Dialysis Modality

64

New Concept for Prescribing a Dialysis Modality

65

Results of the Dialysis Prescription Based on the POD System

66

Rationale of the New Concept for a Dialysis Prescription

67

Practice Pattern for Prescribing Online HDF from a Case Study

71

Conclusion

72

References

72

Optimizing Home Dialysis: Role of Hemodiafiltration

74

Abstract

74

Benefits of HDF over Low-Flux and High-Flux Hemodialysis

77

Individualizing Choice of Renal Replacement Therapy

79

Providing HDF at Home: Technical Considerations

80

Dialysis Adequacy for Home HDF

83

Equipment Portability

84

Conclusion

84

Acknowledgement

84

References

85

Management of Dialysis Fluid and Dialysis System

88

Quality Management of Dialysis Fluid for Online Convective Therapies

88

Abstract

88

Online Preparation of Substitution Solution for Convective Therapies

89

Components of a Quality Management System

91

References

97

Biocompatibility of Dialysis Fluid for Online HDF

99

Abstract

99

Purification of Online Preparation

100

Composition of Dialysis and Substitution Fluids

100

Methods

101

Results

103

Discussion

105

Conclusion

106

References

107

Characteristics of Central Dialysis Fluid Delivery System and Single Patient Dialysis Machine for HDF

109

Abstract

109

Central Dialysis Fluid Delivery System in Japan

109

SPDM in Japan

112

Substitution Fluid for Online HDF with CDDS and SPDM

113

Maintenance of Purification of Dialysis Fluid

114

HD and/or Online HDF Using SPDM by Comprehensive Management

115

Conclusion

116

References

116

Fully Automated Dialysis System for Online Hemodiafiltration Built into the Central Dialysis Fluid Delivery System

117

Abstract

117

Outline of the Central Dialysis Delivery System

118

FADS with Online HDF

119

Fully Automated Dialysis System

119

Dialysis Fluid Quality Control Standards

121

Fluid Quality Control Method

124

Discussion

125

References

126

Uremic Toxins

127

New Uremic Toxins – Which Solutes Should Be Removed?

127

Abstract

127

Toxicity of Specific Uremic Retention Solutes

128

Removal of Protein-Bound Uremic Solutes and Middle Molecules

133

Interventional Outcome Studies Based on Removal

135

Conclusions

136

References

136

Beta-2-Microglobulin as a Uremic Toxin: the Japanese Experience

139

Abstract

139

ß2-Microglobulin and Dialysis-Related Amyloidosis

139

Therapeutic Approaches

140

Conclusion

142

References

142

Markers and Possible Uremic Toxins: Japanese Experiences

144

Abstract

144

Oxidative Stress and AGEs in ESRD

145

Vitamin E-Coated Dialysis Membrane

146

Clinical Effects of Vitamin E-Coated Dialyzer

146

Conclusion

147

References

147

Dialysis Membranes for Hemodiafiltration

149

Biocompatibility of the Dialysis Membrane

149

Abstract

149

Complement Activation

151

Contact Pathway Activation

151

Platelet Activation

151

Monocyte Activation

152

Neutrophil Activation

154

Conclusion

155

References

155

Choice of Dialyzers for HDF

156

Abstract

156

Materials and Method

158

Results and Discussion

158

Conclusions

161

References

161

Estimation of Internal Filtration Flow Rate in High-Flux Dialyzers by Doppler Ultrasonography

163

Abstract

163

Materials and Methods

164

Results

167

Discussions

170

Conclusions

170

References

171

Clinical Aspects of Hemodiafiltration

172

Management of Anemia by Convective Treatments

172

Abstract

172

Pathogenesis of Anemia in Chronic Kidney Disease

173

Anemia and Dialysis Dose

174

Convective Treatments

175

Vitamin E-Coated Membranes

176

Online Treatments

176

Conclusions

180

References

180

Clinical Evaluation Indices for Hemodialysis/Hemodiafiltration in Japan

183

Abstract

183

Historical Review of Chronic HD Therapy in Japan

184

Influence of the Low Prevalence of Renal Transplantation on Chronic HD Therapy in Japan

184

Impacts of High-Flux Membrane Dialyzers on Clinical Indices of HD Patients

185

Impacts of HDF on the Clinical Indices of HD Patients

187

References

188

Effect of Large-Size Dialysis Membrane and Hemofiltration/Hemodiafiltration Methods on Long-Term Dialysis Patients

189

Abstract

189

Development of Protein-Permeable Dialysis Membrane

190

Removal of Uremic Substances and Loss of Albumin in Low MW Protein Region

191

Clinical Efficiency

192

Conclusion

195

References

197

Who Needs Acetate-Free Biofiltration?

198

Abstract

198

Background

198

Concept of Acetate-Free Biofiltration

198

Indication for AFB

199

AFHD vs. AFB

200

Conclusion

202

References

203

Improvement of Autonomic Nervous Regulation by Blood Purification Therapy Using Acetate-Free Dialysis Fluid – Clinical Evaluation by Laser Doppler Flowmetry

205

Abstract

205

Evaluation of Autonomic Function by NICOMM

206

Stability Index of Tissue Blood Flow in the Head

208

Evaluation of Blood Purification Modalities with the Head SI

209

Conclusions

212

References

213

Preservation of Residual Renal Function with HDF

214

Abstract

214

Background

214

Study 1

215

Study 2

216

Study 3

217

Discussion

220

Acknowledgments

221

References

221

Author Index

223

Subject Index

224